Navigation Links
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Date:2/23/2009

I am delighted to join the Micromet Board of Directors and look forward to supporting the company to move to the next stage of its development," said Dr. Dhingra.

"We welcome Dr. Dhingra to the Board of Directors and look forward to his insights and experience in bringing clinical stage antibodies to market," added Christian Itin, Ph.D., Micromet's President and Chief Executive Officer.

Dr. Dhingra received his MBBS degree from the All India Institute of Medical Sciences in 1981 and trained as an intern and resident at New York Medical College from 1983 to 1986. He obtained his medical oncology training at Emory University from 1986 to 1988. He moved to Houston where he joined the faculty of The University of Texas M.D. Anderson Cancer Center, where he conducted clinical and laboratory research in addition to providing patient care. In 1996, Dr. Dhingra joined Eli Lilly and Company as Clinical Research Physician with responsibility for the global development strategy of a novel Selective Estrogen Receptor Modulator. In 1999, he joined Hoffmann-La Roche as Clinical Science Leader. Over the next nine years Dr. Dhingra assumed positions of increasing responsibility, with his last position being Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Throughout his industry career, he maintained an active faculty appointment, initially at Indiana University School of Medicine from 1997 to 1999 and, more recently, at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Dr. Dhingra is currently heading KAPital Consulting LLC, a company dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial promise of the advances in oncology.

About Micromet, Inc.

Micromet, Inc. (www.micro
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... today it has entered into a new gene ... Medical School,s Vector Core. Under the partnership, Sigma-Aldrich ... technology, experimental design consultation, and dedicated gene editing ... accelerate gene editing-based research at the U-M Medical ...
(Date:9/18/2014)... sweeteners, promoted as aids to weight loss and diabetes ... and metabolic disease; and they do it in a ... the gut microbiota the substantial population of bacteria ... experiments in mice and humans, were published today in ... Elinav of the Weizmann Institute,s Immunology Department, who led ...
(Date:9/18/2014)... September 18, 2014 Pipette.com announces ... Sartorius/Biohit, Socorex, Capp, and AccuPet brand of pipettes. ... 100 uL or less and are a great ... applications. , The micropipette promotions were designed ... economic alternative products to help customers find the ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3
... on its recent analysis of new products within the ... the 2012 North American Frost & Sullivan Award for ... a "gold standard" polymerase chain reaction (PCR) instrument. The ... amplification, and detection, all in a multiplexed, automated, and ...
... Inc. (NYSE Amex: BONE ), a leader in ... for medical applications, today announced its financial results for the ... Fourth Quarter 2011 Highlights: Revenue ... for the fourth quarter of 2010. Operating loss decreased ...
... March 21, 2012 When deciding between the ... the upcoming and existing research programs prove highly ... introduces the Life Sciences Content: Pharmaceuticals, Biotechnology, ... to 2012 compendium.  This resource includes Frost ...
Cached Biology Technology:Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 2Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 3Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 2Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 3Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 4Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 5Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 6Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 7Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 8Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 9Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year 10Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon 2Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon 3
(Date:9/16/2014)... 2014)More than $100 trillion in cumulative public and ... dioxide (CO2)a 40 percent reduction of urban passenger ... world expands public transportation, walking and cycling in ... the University of California, Davis, and the Institute ... Further, an estimated 1.4 million early deaths could ...
(Date:9/16/2014)... biology taught us that we inherit certain traits from ... could change how these genes play out by taking ... That,s exactly what a team of researchers at ... through their research of epigenetics research. , Epigenetics ... modifying DNA and histone proteins, which prevent permanent mutations ...
(Date:9/16/2014)... dinosaurs 66 million years ago decimated the evergreens among ... their deciduous peers, according to a study led by ... PLOS Biology . , Applying biomechanical formulas ... of angiosperms flowering plants excluding conifers ... a diverse plant community thriving during a 2.2 million-year ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... known as 'tandem running' to lead another ant from the ... control both the speed and course of the run. It ... 'formal' teaching has been recognised in any non-human animal. , ... information, rather than the constraint of brain size, that has ...
... Neil Ferguson, and Geoff Garnett (of Imperial College London) ... not be controlled through antiretroviral drugs alone, even if ... article in the open-access international medical journal PLoS Medicine, ... their communities about safe sex, access to drugs is ...
... Hopkins researchers have discovered a gene in fruit flies ... bright light. The study, published in the April 4 ... sensory perception in mammals. , In teasing apart the ... studied a gene they dubbed "Lazaro" that is expressed ...
Cached Biology News:First demonstration of 'teaching' in non-human animals 2Access to antiretrovirals unlikely to reduce HIV infection rates 2New gene reduces retinal degeneration in fruit flies 2
Request Info...
... Bean Nuclease catalyzes the degradation of single-stranded ... terminated products. While the nuclease prefers ssDNA ... concentrations the enzyme degrades double-stranded DNA from ... been used for transcript mapping studies (3,4), ...
... fosmid (40kb), and large plasmid insert (10-20kb) ... BAC vector. On command 20-50 fold copy ... DNA purification. Available with blue-white screening (pEZ ... the highest insert stability. Kits include electrocompetent ...
...
Biology Products: